Type 2 diabetes in China: partnerships in education and research to evaluate new antidiabetic treatments.

DSpace/Manakin Repository

Search OPUS

Advanced Search


My Account

Show simple item record

dc.contributor.author Donnelly, R
dc.contributor.author Wang, B
dc.contributor.author Qu, X
dc.date.accessioned 2009-12-21T02:34:18Z
dc.date.issued 2006-06
dc.identifier.citation British journal of clinical pharmacology, 2006, 61 (6), pp. 702 - 705
dc.identifier.issn 0306-5251
dc.identifier.other C1 en_US
dc.identifier.uri http://hdl.handle.net/10453/4662
dc.description.abstract There are 40 million people with diabetes in China, and the projected increase in the rates of obesity and premature cardiovascular disease is alarming. Most patients prefer to combine traditional Chinese medicine with Western medicine, but there is little or no information about the risks and benefits of this approach. Traditional Chinese medicine identifies three patterns of 'depletion-thirst' syndrome and therapy is aimed at reversing the deficiency in yin and qi, using a combination of products tailored to the symptoms and clinical features of individual patients. In Western medicine a number of new oral and injectable antidiabetic therapies are likely to enter routine clinical practice over the next 5 years, for example long-acting GLP-1 analogues, DPP-IV inhibitors and dual PPAR-alpha, PPAR-gamma agonists. To make best use of these agents in China and to promote diabetes education and health service development, there is a need for improved communication and collaboration between universities and hospitals both inside and outside China; and Western pharmacologists and clinicians need a better understanding of traditional Chinese medicine. There are several examples of institutional cooperation that should further diabetes research in China, for example the Beijing Chaoyang Diabetes Hospital linked with Imperial College, London, and the University of Nottingham, which has a new campus in Ningbo, south of Shanghai.
dc.format Print
dc.language eng
dc.relation.isbasedon 10.1111/j.1365-2125.2006.02675.x
dc.title Type 2 diabetes in China: partnerships in education and research to evaluate new antidiabetic treatments.
dc.type Journal Article
dc.parent British journal of clinical pharmacology
dc.journal.volume 6
dc.journal.volume 61
dc.journal.number 6 en_US
dc.publocation Oxford, UK en_US
dc.identifier.startpage 702 en_US
dc.identifier.endpage 705 en_US
dc.cauo.name SCI.Medical and Molecular Biosciences en_US
dc.conference Verified OK en_US
dc.for 1115 Pharmacology and Pharmaceutical Sciences
dc.personcode 980838
dc.percentage 100 en_US
dc.classification.name Pharmacology and Pharmaceutical Sciences en_US
dc.classification.type FOR-08 en_US
dc.custom 2.8 en_US
dc.description.keywords Humans
dc.description.keywords Diabetes Mellitus, Type 2
dc.description.keywords Drug Design
dc.description.keywords Hypoglycemic Agents
dc.description.keywords Medicine, Chinese Traditional
dc.description.keywords Interinstitutional Relations
pubs.embargo.period Not known
pubs.organisational-group /University of Technology Sydney
pubs.organisational-group /University of Technology Sydney/Faculty of Science
pubs.organisational-group /University of Technology Sydney/Strength - Health Technologies
pubs.organisational-group /University of Technology Sydney/Strength - Health Technologies
utslib.copyright.status Closed Access
utslib.copyright.date 2015-04-15 12:17:09.805752+10
pubs.consider-herdc true
utslib.collection.history School of Medical and Molecular Sciences (ID: 341)
utslib.collection.history Closed (ID: 3)

Files in this item

This item appears in the following Collection(s)

Show simple item record